natgillin/translations-raw huggingface dataset:
A composition as claimed in Claim 33, wherein the antioxidant is a-tocopherol, ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, fumaric acid, malic acid, monothioglycerol, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, potassium metabisulfite, sodium sulfite, tartaric acid and/or vitamin E. 
Kompozicija prema zahtjevima 33, naznačena time što je antioksidans a-tokoferol, askorbinska kiselina, butilni hidroksianizol, butilni hidroksitoluen, limunska kiselina, fumarna kiselina, jabučna kiselina, monotioglicerol, propionska kiselina, propil galat, natrij askorbat, natrij bisulfit, natrij metabisulfit, kalij metabisulfit, natrij sulfit, vinska kiselina i/ili vitamin E.
A composition as claimed in Claim 33, wherein the chelating agent is ethylenediaminetetraacetic acid, ethylenediaminetriacetic acid and/or diethylenetriaminepentaacetic acid. 
Kompozicija prema zahtjevu 33, naznačena time što je sredstvo za kelatiranje etilendiamintetraoctena kiselina, etilendiamintrioctena kiselina i/ili dietilentriaminpentaoctena kiselina.
A composition as claimed in Claim 33, wherein the preservative is benzalkonium chloride, benzoic acid, butylated hydroxyanisole, butylparaben, chlorbutanol, ethylparaben, methylparaben, propylparaben, phenoxyethanol and/or phenylethyl alcohol. 
Kompozicija prema zahtjevu 33, naznačena time što je konzervans benzalkonij klorid, benzojeva kiselina, butilni hidroksianizol, butilparaben, klorbutanol, etilparaben, metilparaben, propilparaben, fenoksietanol i/ili feniletil alkohol.
A composition as claimed in Claim 33, wherein the viscosity-increasing agent is polyethyleneglycol, crosslinked polyvinylpyrrolidone and/or hydroxypropylmethyl cellulose. 
Kompozicija prema zahtjevu 33, naznačena time što je sredstvo koje povećava viskoznost polietilen glikol, umreženi polivinilpirolidon i/ili hidroksipropilmetil celuloza.
adding a polar lipid or a mixture of polar lipids that is/are swellable in aqueous media to an aqueous solution of cetirizine with stirring; and 
dodavanje polarnog lipida ili mješavine polarnih lipida koji bubri(e) u vodenom mediju u vodenu otopinu cetirizina uz miješanje; i
A process as claimed in Claim 40, wherein, prior to the homogenisation step, the pH is adjusted to the desired value by adding an acid or a base. 
Postupak prema zahtjevu 40, naznačen time što je prije stupnja homogenizacije, pH podešen na željenu vrijednost dodavanjem kiseline ili baze.
A process as claimed in Claim 42 (as dependent on Claim 41), wherein the addition of water, saline or buffer takes place after the pH adjusting step. 
Postupak prema zahtjevu 42 (koji je zavisan od zahtjeva 41), naznačen time što se dodatak vode, otopine soli ili pufera odvija poslije stupnja podešavanja pH.
A process as claimed in any one of Claims 40 to 44, wherein the aqueous solution of cetirizine is formed either by adding buffer to an aqueous solution of cetirizine or salt thereof, or adding cetirizine or salt thereof to an aqueous buffer solution, prior to the addition of lipid. 
Postupak prema bilo kojem od zahtjeva 40 do 44, naznačen time što je vodena otopina ceterizina stvorena ili dodavanjem pufera u vodenu otopinu cetririzina ili njegove soli, ili dodavanjem cetirizina ili njegove soli u vodenu otopinu pufera, prije dodavanja lipida.
A process as claimed in any one of Claims 40 to 46, wherein the homogenisation step (b) comprises vigorous mechanical mixing, high speed homogenisation, shaking, vortexing and/or rolling. 
Postupak prema jednom od zahtjeva 40 do 46, naznačen time što homogenizacijski stupanj (b) obuhvaća intenzivno mehaničko miješanje, homogenizaciju pri visokoj brzini, mućkanje, miješanje na vorteksu i/ili valjanje.
A process as claimed in Claim 48, wherein the size-reduction step comprises extrusion through a membrane filter. 
Postupak prema zahtjevu 48, naznačen time što stupanj smanjenja veličine obuhvaća ekstruziju kroz membranski filter.
A homogeneous pharmaceutical composition comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier, wherein cetirizine is distributed throughout the whole composition in a concentration in the aqueous medium that varies by no more than ±50% when comparing concentrations inside and outside of the liposomal structures obtainable by a process as defined in any one of Claims 40 to 50. 
Homogena farmaceutska kompozicija koja sadrži cviterionski cetirizin, polarni lipidni liposom i farmaceutski prihvatljiv vodeni nosač, gdje je cetirizin raspoređen kroz cijelu kompoziciju u koncentraciji u vodenom mediju koja varira ne više od ±50% kada se usporedi sa koncentracijama unutar ili izvan liposomalnih struktura koje su dobivene postupkom koji je definiran prema bilo kojem zahtjevu 40 do 50.
A composition as defined in any one of Claims 1 to 39 or 51 for use in the treatment of rhinitis, which treatment comprises the administration of that composition to a person suffering from or susceptible to:hat disorder. 
Kompozicija prema bilo kojem od zahtjeva 1 do 39 ili 51, za primjenu u liječenju rinitisa, koji obuhvaća davanje kompozicije osobi koja pati ili je podložena tom poremećaju.
The process as claimed in any one of claims 1 to 3, wherein step (i) is conducted in the presence of a palladium catalyst selected from the group consisting of tetrakis(triphenylphosphine)palladium, palladium on activated charcoal, and palladium on alumina. 
Postupak kako je prijavljen u patentnim zahtjevima 1 do 3, naznačen time da se korak (i) provodi u prisutnosti paladija kao katalizatora odabranog od sljedećih: tetrakis(trifenilfosfin)paladj, paladij na aktivnom ugljenu ili paladij na aluminijevom oksidu.
The process as claimed in claim 7, wherein the compound of formula (I) is 1-(3',4'-dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid 
Postupak kako je prijavljen u patentnom zahtjevu 7, naznačen time da spoj formule (I) jest 1-(3’,4’-diklor-2-fluor[1,1’-bifenil]-4-il)-ciklopropankarboksilna kiselina.
A compound of claim 1 for use according to claim 1 wherein the treatment and/or prevention of acute diverticulitis is in patients affected by colonic diverticulosis, indeterminate colitis and infectious colitis. 
Spoj prema patentnom zahtjevu 1 za uporabu prema patentnom zahtjevu 1, pri čemu je liječenje i/ili prevencija akutnog divertikulitisa kod bolesnika pogođenih divertikulozom debelog crijeva, neodređenim kolitisom i infektivnim kolitisom.
A compound of claim 1 for use according to claim 1 or claim 2 wherein the compound is 2-methoxy-3-(4'-aminophenyl)propionic acid. 
Spoj prema patentnom zahtjevu 1 za uporabu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu je spoj 2-metoksi-3-(4’-aminofenil)propionska kiselina.
A compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein u and u' are independently 0, 1, 2, or 3; 
Spoj Formule (I) [image] ili njegova farmaceutski prihvatljiva sol, gdje u i u’ su nezavisno 0, 1, 2, ili 3;
D and D' are each independently selected from NR5, O, and S; wherein each R5 is independently selected from hydrogen, alkoxycarbonyl, alkyl, arylalkoxycarbonyl, carboxy, haloalkyl, hydroxy, (NRaRb)carbonyl, and trialkylsilylalkoxyalkyl; 
D i D’ su svaki nezavisno izabrani između NR5, O, i S; gdje svaki R5 je nezavisno izabran između vodika, alkoksikarbonil, alkil, arilalkoksikarbonil, karboksi, haloalkil, hidroksi, (NRaRb)karbonil, i trialkilsililalkoksialkil;
R2' and R3', together with the carbon atoms to which they are attached, form a five- to eight-membered aromatic or non-aromatic ring optionally containing one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the five- to eight-membered ring is optionally substituted with one, two, or three substitutents independently selected from alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylsulfonyl, aryl, arylalkyl, arylsulfonyl, carboxy, formyl, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, -NRaRb, (NRaRb)alkyl, (NRaRb)carbonyl, oxo, and spirocycle; 
’ i R3’, zajedno s atomima ugljika na koje su vezani, formiraju petero- do osmeročlani aromatski ili nearomatski prsten koji po izboru sadrži jedan ili dva heteroatoma nezavisno izabrana između dušika, kisika, i sumpora; gdje je petero- do osmeročlani prsten po izboru supstituiran jednim, dva ili tri supstituenta nezavisno izabrana između alkoksi, alkoksialkil, alkoksikarbonil, alkil, alkilsulfonil, aril, arilalkil, arilsulfonil, karboksi, formil, halo, haloalkoksi, haloalkil, hidroksi, hidroksialkil, -NRaRb, (NRaRb)alkil, (NRaRb)karbonil, okso, i spirocikl;
each R6 is independently selected from alkoxy, alkyl, aryl, halo, haloalkyl, hydroxy, and -NRaRb, wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups; 
svaki R6 je nezavisno izabran između alkoksi, alkil, aril, halo, haloalkil, hidroksi, i -NRaRb, gdje alkil može po izboru formirati fuzionirani tri- do šesteročlani prsten sa susjednim atomom ugljika, gdje je tri- do šesteročlani prsten po izboru supstituiran jednom ili dvije alkilne skupine;
Re and Rf are independently selected from hydrogen, alkyl, unsubstituted aryl, unsubstituted arylalkyl, unsubstituted cycloalkyl, unsubstituted (cyclolalkyl)alkyl, unsubstituted heterocyclyl, unsubstituted heterocyclylalkyl, (NRxRy)alkyl, and (NRxRy)carbonyl; and Rx and Ry are independently selected from hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, unsubstituted aryl, unsubstituted arylalkoxycarbonyl, unsubstituted arylalkyl, unsubstituted cycloalkyl, unsubstituted heterocyclyl, and (NRx'Ry')carbonyl, wherein Rx' and Ry' are independently selected from hydrogen and alkyl. 
Re i Rf su nezavisno izabrani između vodika, alkil, nesupstituiranog arila, nesupstituiranog arilalkila, nesupstituiranog cikloalkila, nesupstituiranog (ciklolalkil)alkila, nesupstituiranog heterociklila, nesupstituiranog heterociklilalkila, (NRxRy)alkila, i (NRxRy)karbonila; i Rx i Ry su nezavisno izabrani između vodika, alkoksikarbonil, alkil, alkilkarbonil, nesupstituiranog arila, nesupstituiranog arilalkoksikarbonila, nesupstituiranog arilalkila, nesupstituiranog cikloalkila, nesupstituiranog heterociklila, i (NRx’Ry’)karbonila, gdje Rx’ i Ry’ su nezavisno izabrani između vodika i alkila.
A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 and R3, together with the carbon atoms to which they are attached, form a six- or seven-membered carbocyclic ring. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje R2 i R3, zajedno s atomima ugljika na koje su vezani, formiraju šestero- ili sedmeročlani karbociklički prsten.
The composition of claim 11 wherein at least one of the additional compounds is an interferon which is preferably selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau or a ribavirin. 
Smjesa prema zahtjevu 11 gdje je barem jedan od dodatnih spojeva interferon poželjno izabran između interferona alfa 2B, pegiliranog interferona alfa, konsenzus interferona, interferona alfa 2A, i limfoblastoidnog interferona tau ili ribavirina.
The compound for use according to claim 13 further comprising using one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj za uporabu prema zahtjevu 13 koja dalje obuhvaća uporabu jednog ili dva dodatna spoja koja imaju anti-HCV aktivnost, prije, nakon ili istodobno sa spojem prema zahtjevu 1, ili or njegovom farmaceutski prihvatljivom soli.
The compound for use according to claim 14 wherein at least one of the additional compounds is an interferon which is preferably selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau or a ribavirin. 
Spoj za uporabu prema zahtjevu 14 gdje je barem jedan od dodatnih spojeva interferon poželjno izabran između interferona alfa 2B, pegiliranog interferona alfa, konsenzus interferona, interferona alfa 2A, i limfoblastoidnog interferona tau ili ribavirina.
The pharmaceutical composition of claim 8, comprising a pharmaceutically acceptable carrier and optionally further comprising another therapeutic agent. 
Farmaceutska kompozicija prema patentnom zahtjevu 8, koja sadrži farmaceutski prihvatljiv nosač i koja izborno dodatno sadrži drugo terapeutsko sredstvo.
Use of a serum-free culture medium for reducing the levels of oxidized forms of a recombinant dimeric gonadotropin during its manufacturing process wherein said culture medium comprises an antioxidant selected from the group consisting of: 
Uporaba kultiviranog medija bez seruma za smanjivanje razina oksidiranih oblika rekombinantnog dimernog gonadotropina tijekom njegovog proizvodnog procesa naznačena time da navedeni kultivirani medij sadrži antioksidans koji je odabran iz skupine koja sadrži:
2-mercaptoethanol at a concentration ranging from about 5 to about 15 mg/L; 
-merkaptoetanol u koncentraciji u rasponu od oko 5 do oko 15 mg/L;
The use according to claim 1, wherein said antioxidant is selected from the group consisting of: 
Uporaba prema zahtjevu 1, naznačena time da je navedeni antioksidans odabran iz skupine koja sadrži:
L-glutathione at a concentration of about 3 mg/L; 
L-glutation u koncentraciji od oko 3 mg/L;
2-mercaptoethanol at a concentration of about 10 mg/L; 
-merkaptoetanol u koncentraciji od oko 10 mg/L;
Process according to claim 1, wherein step iv) is carried out in the presence of reducing agents of the tin, borate and derivatives or ascorbic acid type. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se korak iv) provodi u prisutnosti reducensa tipa kositra, borata i njegovih derivata ili tipa askorbinske kiseline.
Composition according to claim 3, wherein the polysaccharide is in the form of particles. 
Pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polisaharid u obliku čestica.
A compound according to claim 1 selected from the group 
Spoj prema zahtjevu 1 naznačen time da je odabran iz skupine
Process for the preparation of compounds of formula (I) according to Claims 1-11 and solvates, salts and stereoisomers thereof, characterised in that a compound of formula (II) wherein R1, R2 and B1 have the meanings indicated in claim 1 and X is Cl, Br or I, is reacted in a Suzuki reaction with a boronic acid derivative B2-B(OH)2, in which B2 has the meaning indicated in claim 1, and/or a base or acid of the formula I is converted into one of its salts. 
Postupak za dobivanje spojeva formule (I) prema zahtjevima 1-11 i njegovih solvata, soli i stereoizomera, naznačen time da spoj formule (II) [image] pri čemu R1, R2 i B1 imaju značenja navedena u zahtjevu 1 i X is Cl, Br ili I, reagira u Suzukijevoj reakciji sa derivatom boronske kiseline B2-B(OH)2, gdje B2 ima značenje navedeno u zahtjevu 1, i/ili baza ili kiselina formule I je pretvorena u jednu od njegovih soli.
Use of compounds according to Claim 1-11, and salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of metabolic syndrome, diabetes, obesity, cancer, inflammation, cardiovascular diseases. 
Uporaba spojeva prema zahtjevu 1-11, te njegovih soli, solvata i stereoizomera, uključujući njihove smjese u svim omjerima, naznačena time da je za dobivanje lijeka za liječenje metaboličkog sindroma, dijabetesa, pretilosti, raka, upale, kardiovaskularnih bolesti.
Use of compounds according to claim 1-11 for the preparation of a medicament increasing the uptake of glucose in muscular cells. 
Uporaba spojeva prema zahtjevu 1-11 naznačena time da je za dobivanje lijeka za povećavanje unosa glukoze u mišićne stanice.
Package according to claim 15, characterised in that the reinforcement insert is formed as a plastic container, preferably made by injection-moulding. 
Omot za pakiranje u skladu s patentnim zahtjevom 15, naznačen time što je pojačani umetak načinjen kao plastični spremnik, za koji je poželjno da je načinjen pomoću lijevanja injektiranjem.
Package according to anyone of claims 1 to 20, characterised in that, opposite to the cutout (20; 93; 103) of the outer shell (2; 92; 102), the inner shell (6; 96; 106, 107) comprises a grip-enhancing surface, which preferably includes at least one of the following features: relief structure, cutout structure, high-friction coating, rubber-like coating. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačen time što unutarnja ljuska (6; 96; 106, 107) ima na strani koja se nalazi nasuprot izrezanom dijelu (20; 93; 103) vanjske ljuske (2; 92; 102) površinu koja ima poboljšana svojstva s obzirom na zahvaćanje, za koju površinu je poželjno da uključuje najmanje jedno od sljedećih svojstava: reljefnu strukturu, strukturu s urezima, premaz koji ima veliko trenje, premaz koji je sličan gumi.
Package according to anyone of claims 1 to 23, characterised in that the outer shell (2; 92; 102) and/or the inner shell (6; 96; 106, 107) are folded from a respective blank (60, 70; 84, 86) made from cardboard in the weight range from 180 g/m2 to 290 g/m2. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 23, naznačen time što su vanjska ljuska (2; 92; 102) i/ili unutarnja ljuska (6; 96: 106, 107) savijene iz odgovarajućeg prireza razvijenog oplošja (60; 70; 84, 86), koji prirez je načinjen od kartona koji se nalazi u području mase od 180 g/m2 do 290 g/m2.
The method of claim 1, wherein the intimate mixture is obtained by joint cryomilling of the crystalline substance and the polymer. 
Postupak prema zahtjevu 1, gdje se bliska smjesa dobiva zajedničkim krio-mljevenjem kristalne tvari i polimera.
The method of claim 1, comprising recording the DSC dissolution endotherm at a plurality of heating rates and extrapolating Tend to zero heating rate. 
Postupak prema zahtjevu 1, obuhvaća bilježenje DSC endoterme otapanja u više brzina zagrijavanja i ekstrapolaciju Tend na nultu brzinu zagrijavanja.
plotting Tend over the composition of the mixtures. 
ucrtavanje Tend po sastavu smjesa.
determining the solubility at Tg as the intersection of the Tend plot and the Tg plot. 
određivanje topljivosti pri Tg kao presjeka Tend grafa i Tg grafa.
The method of claim 5, wherein the crystalline substance is a pharmaceutically active ingredient. 
Postupak prema zahtjevu 5, gdje je kristalna tvar farmaceutski djelatna tvar.
determining an upper concentration limit as the solubility of the crystalline substance in the polymer at Tg, 
određivanje gornje granice koncentracije kao topljivosti kristalne tvari u polimeru pri Tg,
assigning a solid solution whose drug loading is below the upper concentration limit as likely stable against crystallization 
određivanje čvrste otopine čiji je sastav lijeka ispod gornje granice koncentracije kao vjerojatno stabilne na kristalizaciju.
The method of claim 8, wherein the dosage form is stored at temperatures below the Tg of the solid solution if the drug loading of the solid solution exceeds the upper concentration limit. 
Postupak prema zahtjevu 8, gdje se dozirni oblik čuva pri temperaturama nižim od Tg čvrste otopine ako sastav lijeka čvrste otopine prelazi gornju granicu koncentracije.
A method of distributing a personal code to a user of a financial instrument associated with said personal code, comprising, after a step of sending to the user, via a first channel, a request code associated with said personal code, 
Postupak distribucije osobnog koda korisniku financijskog instrumenta povezanog sa navedenim osobnim kodom, koji sadrži, nakon koraka slanja prema korisniku, putem prvog kanala, koda zahtjeva povezanog sa navedenim osobnim kodom,
a step of retrieving the personal code (210) associated with said request code 260 and 
korak dohvaćanja osobnog koda (210) povezanog sa navedenim kodom zahtjeva 260,te
wherein the second channel and the third channel are a mobile telephone network (170), wherein the second channel is a network for transmitting short messages and wherein the step of retrieving the personal code includes a step of checking the user mobile phone number (205) in the second channel. 
korak slanja korisniku dohvaćenog osobnog koda (210) putem trećeg kanala, pri čemu su drugi kanal i treći kanal pokretna telefonska mreža (170), te pri čemu je drugi kanal mreža za prijenos kratkih poruka, a pri čemu korak prijema osobnog koda uključuje korak provjere mobilnog telefonskog broja (205) korisnika u drugom kanalu.
An information storage means that can be read by a computer or a microprocessor storing instructions of a computer program, that permits the implementation of a method according to any one of claims 1 to 5. 
Sredstva za pohranu informacija koja mogu biti pročitana putem pohranjenih instrukcija u računalu ili mikroprocesoru u vidu računalnog programa, naznačena time da omogućavaju primjenu postupka prema bilo kojem od zahtjeva 1 do 5.
A computer program loadable into a computer system, said program containing instructions enabling the implementation of the method according to any one of claims 1 to 5, when that program is loaded and executed by a computer system. 
Računalni program koji se može učitati u računalni sustav, naznačen time da navedeni program sadrži instrukcije koje omogućavaju primjenu postupka prema bilo kojem od zahtjeva 1 do 5, kada je navedeni program učitan i izvršava se na računalnom sustavu.
Y is hydrogen or an optionally substituted straight or branched (C1-C3) alkyl; 
Y je vodik ili izborno supstituirani nerazgranati ili razgranati (C1-C3) alkil;
and R' and R" are independently hydrogen or an optionally further substituted straight or branched (C1-C6) alkyl, or taken together with the carbon atom to which they are bonded R' and R" may form an optionally substituted (C3-C8) cycloalkyl; 
i R' i R'' su neovisno vodik ili izborno dodatno supstituiran nerazgranati ili razgranati (C1-C6) alkil, ili uzeti zajedno s atomom ugljika na kojeg su vezani R' i R'' mogu tvoriti izborno supstituirani (C3-C8) cikloalkil;
m is an integer from 0 to 2. 
m je cijeli broj od 0 do 2.
A compound of formula (I) as defined in claims 1 to 3 wherein: 
Spoj formule (I) u skladu s patentnim zahtjevima 1 do 3, naznačen time što:
is an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C3-C8) cylcoalkyl, (C3-C8) cycloalkenyl, heterocyclyl, aryl and heteroaryl. 
je izborno supstituirana skupina, koju se bira između nerazgranatog ili razgranatog (C1-C8) alkila, (C3-C8) cikloalkila, (C3-C8) cikloalkenila, heterociklila, arila i heteroarila.
A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claims 1 to 8 which is selected from the group consisting of: 
Spoj formule (I), ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 8, naznačen time što ga se bira iz skupine koju čine:
A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, and at least one pharmaceutically acceptable excipient, carrier and/or diluent. 
Farmaceutski pripravak, naznačen time što sadrži terapijski djelotvornu količinu spoja formule (I), ili njegove farmaceutski prihvatljive soli, u skladu s patentnim zahtjevom 1, i najmanje jednu farmaceutski prihvatljivu pomoćnu tvar, podlogu i/ili razrjeđivač.
A product or kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, or pharmaceutical compositions thereof as defined in claim 11 and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy. 
Proizvod ili komplet, naznačen time što sadrži spoj formule (I), ili njegovu farmaceutski prihvatljivu sol, u skladu s patentnim zahtjevom 1, ili njegove farmaceutske pripravke u skladu s patentnim zahtjevom 11 i jedno ili više kemoterapijskih sredstava, kao kombinirani pripravak za istodobnu, odvojenu ili uzastopnu upotrebu u antikanceroznoj terapiji.